Clinical Trial Update: Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

View source ↗

Summary

A trial update notes the completion of a study evaluating a third-generation EGFR-TKI in metastatic EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Third-generation EGFR-TKI

Snippet

Sponsor: Fudan University | Conditions: Third-generation TKI, NSCLC (Advanced Non-small Cell Lung Cancer) | Status: COMPLETED